Merck KGaA, Darmstadt, Germany, and Pfizer Inc announced that the Phase III JAVELIN Gastric 300 trial did not meet its...
Read moreBiogen and Alkermes plc announced that they have entered into a global license and collaboration agreement to develop and commercialize...
Read moreChronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults. It is due to the growth of...
Read moreAstraZeneca announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company...
Read moreExelixis has announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018...
Read moreBiondVax Pharmaceuticals Ltd. has announced the signing of the clinical trial agreement (CTA) for a phase 2 clinical trial with...
Read moreAt the 5th Canton Nucleic Acids Forum (CNAF) in Guangzhou, China, Guangzhou RiboBio Co., Ltd. ("RiboBio") and GE Healthcare Life...
Read moreArvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, and Macroceutics, Inc., today...
Read moreRoche has announced that the phase III IMpower150 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that...
Read moreChugai Pharmaceutical has announced that the primary endpoint has been met for the global phase III HAVEN 3 (NCT02847637) study...
Read morePharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.